SHOCKWAVE MEDICAL, INC.

(SWAV)
  Report
Delayed Nasdaq  -  04:00 2022-08-12 pm EDT
289.13 USD   +2.70%
08/12PUMP / DUMP #41 : This week's gainers and losers
MS
08/09SECTOR UPDATE : Health Care Stocks Little Changed Late in Tuesday Trade
MT
08/09SECTOR UPDATE : Health Care Stocks Posting Modest Tuesday Advance
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ShockWave Medical, Inc.(NasdaqGS:SWAV) added to S&P 400 Health Care

06/21/2022 | 12:00am EDT

ShockWave Medical, Inc.(NasdaqGS:SWAV) added to S&P 400 Health Care (Sector)


© S&P Capital IQ 2022
All news about SHOCKWAVE MEDICAL, INC.
08/12PUMP / DUMP #41 : This week's gainers and losers
MS
08/09SECTOR UPDATE : Health Care Stocks Little Changed Late in Tuesday Trade
MT
08/09SECTOR UPDATE : Health Care Stocks Posting Modest Tuesday Advance
MT
08/09Top Midday Gainers
MT
08/09SECTOR UPDATE : Health Care
MT
08/09ShockWave Medical Swings to Profit After Sales More Than Double in Q2; Shares Rise Tues..
MT
08/09Morgan Stanley Adjusts Price Target on ShockWave Medical to $255 From $201, Keeps Equal..
MT
08/09Canaccord Genuity Adjusts Price Target on ShockWave Medical to $256 From $232, Reiterat..
MT
08/09Wells Fargo Adjusts Price Target on ShockWave Medical to $255 From $176, Reiterates Ove..
MT
08/09Piper Sandler Adjusts Price Target on ShockWave Medical to $278 From $245, Reiterates O..
MT
More news
Analyst Recommendations on SHOCKWAVE MEDICAL, INC.
More recommendations
Financials (USD)
Sales 2022 476 M - -
Net income 2022 98,1 M - -
Net cash 2022 241 M - -
P/E ratio 2022 112x
Yield 2022 -
Capitalization 10 388 M 10 388 M -
EV / Sales 2022 21,3x
EV / Sales 2023 16,2x
Nbr of Employees 657
Free-Float 98,8%
Chart SHOCKWAVE MEDICAL, INC.
Duration : Period :
ShockWave Medical, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHOCKWAVE MEDICAL, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 289,13 $
Average target price 255,67 $
Spread / Average Target -11,6%
EPS Revisions
Managers and Directors
Douglas Evan Godshall President, Chief Executive Officer & Director
Daniel Puckett Chief Financial Officer & Secretary
C. Raymond Larkin Chairman
Beaux Alexander Vice President-Clinical Affairs
W. Patrick Stephens Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
SHOCKWAVE MEDICAL, INC.62.13%10 388
NOVOCURE LIMITED14.44%8 999
MASIMO CORPORATION-47.27%8 109
PENUMBRA, INC.-40.13%6 518
GETINGE AB-43.33%5 975
IRAY TECHNOLOGY COMPANY LIMITED1.03%5 401